While many of these biomarkers have been successfully used for internal decision-making and early proof-of-concept studies, relatively few of these biomarkers have left the pharmaceutical space for wider clinical utilisation.
This is set to change as a growing number of biomarkers are being codeveloped along with the therapeutic compound as companion diagnostics; this is part of the Precision Medicine paradigm of delivering the right medicine to the right patient.
This development will undoubtedly move biomarkers beyond the pharmaceutical space and into the clinical laboratory, thus influencing the practice of laboratory medicine. This is where clinical chemists at laboratories such as Affinity Biomarker Labs can play their part.
By combining analytical rigour and clinical expertise, Affinity Biomarker Labs focuses on supporting biopharma to develop a broader range of useful biomarkers; not only for drug development but ultimately for use in the clinical laboratory.